IFFO1: A Potential Drug Target for Cancer (G25900)

Target Name: IFFO1

NCBI ID: G25900

IFFO1

IFFO1: A Potential Drug Target for Cancer

IFFO1 (Non-Homologous End Joining Factor I) is a protein that plays a critical role in the process of DNA replication in eukaryotic cells. It is a key component of the complex protein filament IP3-dependent DNA replication machinery, which is responsible for copying the genetic information of the cell's DNA. IFFO1 helps to ensure that the two new strands of DNA are accurately joined together, which is essential for the stability and accuracy of the replication process.

As a result of its role in DNA replication, IFFO1 has been identified as a potential drug target for diseases that involve DNA replication disorders, such as cancer. The development of new treatments for cancer often involves targeting the genes that are responsible for the survival and growth of cancer cells, and IFFO1 is one of these genes.

One of the key advantages of IFFO1 as a drug target is its relatively simple structure. IFFO1 is a single gene that encodes a protein of 14 kDa, which makes it relatively easy to synthesize and purify. This has allowed researchers to study its function at the molecular level and to develop potential treatments for cancer.

In addition, IFFO1 is well-validated as a drug target. Studies have shown that IFFO1 is highly expressed in various types of cancer, including breast, ovarian, and colorectal cancers. Additionally, IFFO1 has been shown to be involved in the regulation of cell Cycle progression, which is a critical step in the development of cancer.

Another potential advantage of IFFO1 as a drug target is its ability to act as a biomarker. By measuring the levels of IFFO1 in cancer cells, researchers can monitor the effectiveness of new treatments and track their progress. This can be especially important in the context of cancer, where accurate monitoring of the disease's progression is critical for effective treatment.

In conclusion, IFFO1 is a protein that has the potential to be a drug target for cancer. Its simple structure and high expression in various types of cancer make it an attractive target for researchers, and its role in cell cycle regulation also adds to its potential as a biomarker. Further research is needed to fully understand the functions of IFFO1 and to develop effective treatments for cancer.

Protein Name: Intermediate Filament Family Orphan 1

Functions: Nuclear matrix protein involved in the immobilization of broken DNA ends and the suppression of chromosome translocation during DNA double-strand breaks (DSBs) (PubMed:31548606). Interacts with the nuclear lamina component LMNA, resulting in the formation of a nucleoskeleton that relocalizes to the DSB sites in a XRCC4-dependent manner and promotes the immobilization of the broken ends, thereby preventing chromosome translocation (PubMed:31548606). Acts as a scaffold that allows the DNA repair protein XRCC4 and LMNA to assemble into a complex at the DSB sites (PubMed:31548606)

The "IFFO1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IFFO1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets